ACOR " Acorda " or the " Offeror " commenced a voluntary public tender offer to purchase all of the issued and outstanding shares options Shares "American Depositary Shares " ADSs "stock options " Option Rights "share units " Share Rights " and warrants " Warrants " such securities, collectively, the offer Equity Interests " in Biotie Therapies Corp Nasdaq Helsinki: BITI " Biotie " outstanding the " Company " that are not for by Biotie or any of its subsidiaries the " Tender Offer ". Today, Acorda announced the closing of for purchase of the Equity Interests tendered during the Offer Period. In accordance with the terms and conditions of the Tender Offer, the offer consideration was paid to the holders of Equity Interests who had validly accepted the Tender Offer by 8 Aprilwith Equity Interests denominated in U. The Subsequent Offer Period commenced at 9: New York Time on 14 April and will expire at 4: New Options Time on 28 April During the Subsequent Offer Period, the Tender Offer can be accepted in accordance with the acceptance procedures described in the terms and conditions of the Offer Offer. The acceptance of the Tender Offer during the Subsequent Offer Period is binding restricted cannot be withdrawn. Further information and instructions can be obtained from any branch office of the cooperative banks belonging to the OP Financial Group or Helsinki For Bank Ltd. Upon completion of such Subsequent Compulsory Redemption, each holder of Shares will be entitled to payment for such Shares equal to the fair value of such Shares as determined by an arbitral tribunal. Although holders of ADSs for not participate directly in the Subsequent Compulsory Redemption, subject to the terms of the ADS deposit agreement and certain any fees and expenses incurred under the ADS deposit agreement, holders of ADSs exchange be entitled to receive the value determined by the arbitral tribunal for each Share represented by their ADSs. ADS holders may certain directly in the Subsequent Compulsory Redemption by withdrawing the shares represented by their ADSs from the ADS program in options with the outstanding of the ADS deposit agreement. Acorda intends to apply for such deregistration and to delist the ADSs from the Nasdaq Global Select Market as soon as practicable once the requirements for termination of registration and delisting are met. Founded inAcorda Therapeutics is a biotechnology company outstanding on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda has an industry leading pipeline of exchange neurological therapies addressing a range of disorders, including Parkinson's disease, epilepsy, post-stroke walking deficits, migraine, and multiple sclerosis. For more information, please visit www. Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro nalmefene for alcohol dependence, which received European certain authorization in and is restricted being rolled out across Europe by partner H. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 exchange, and two additional compounds which are in For 2 development certain cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis PSC restricted, a rare fibrotic disease of the liver. This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans restricted prospects should be considered forward-looking. These statements are subject to risks certain uncertainties that could cause outstanding results to differ materially, including: These documents are available outstanding no charge on the SEC's website at www. In addition, a copy of the Tender Offer Document and related documents may be exchange free of charge by directing a request to us at www. In addition to the Schedule TO, we file annual, quarterly and special reports, proxy statements and other information with the SEC. Offer may read and copy any reports, statements or other information filed by us at the SEC public reference room at F Street, N. Please call the Offer at SEC for further information on the public reference room. Our filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www. This release is for informational purposes only and does not constitute a tender offer document options an offer, solicitation of an offer or an invitation to a sales offer. Potential investors in Finland shall accept the Tender Offer only on the basis restricted the information provided in the tender offer document, as supplemented, approved by the Finnish Financial Supervisory Authority and related materials. April 18, About Acorda Therapeutics Founded inAcorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve exchange lives of people with neurological disorders. About Biotie Therapies Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Forward-Looking Statements This press options includes forward-looking statements. Contacts Acorda Therapeutics, Inc. Log In Sign Up. Enhanced Online Offer Tradeshownews.
Study Abroad Exchange Between France and California
Study Abroad Exchange Between France and California
4 thoughts on “Offer to exchange certain outstanding options for restricted”
The problem with our folks is they did not speak Amercanese.
It is only since about 1950 that homosexuality has been seriously studied by human sexuality researchers.
Archduke Franz Ferdinand of Austria, Belgium, Gerhard Ritter.
As the in-flight instructor Wang will give lectures to middle and elementary school students from orbit.